World Journal of Psychiatry
June 30, 2026
Ling Zhu, Lu-Yao Ji, Chao Shi et al.
BACKGROUND Anxiety and depression are prevalent and often co-occurring mental health disorders. While mindfulness training has shown efficacy in reducing symptoms, the underlying mechanisms, particularly the role of psychological resilience, remain underexplored. This study investigates whether mindfulness training alleviates anxiety and depression and hypothesizes that psychological resilience...
Journal of Rawalpindi Medical College
June 30, 2026
Aashi Mughal, Anwar Bibi, Asifa Afzal et al.
Objective: Medical students experience high psychological demands that predispose them to stress, anxiety, and depression. This study aimed to determine the prevalence of stress, anxiety, and depression in 4th-year MBBS students and measure the efficacy of a short-term mindfulness-based life coaching (MBLC) intervention. Methods: This study consisted of a cross-sectional screening followed by a...
Psychosomatic Medicine and General Practice
June 30, 2026
Viacheslav Zaika, Yan Tytarenko
Background. Ketamine provides rapid but short-lived antidepressant effects for treatment-resistant depression (TRD). To prolong this response, ketamine-assisted therapy (KAT) combines the drug's pharmacological effects with psychotherapy. Aim. This study aims to analyze scientific evidence regarding the synergistic interaction between ketamine's pharmacological effects and modern...
Asian Journal of Medical Sciences
June 30, 2026
Raja Suhail Shounthoo, Ajaiz Rasool, Athar Un Nisa Quraishi et al.
Ketamine, a dissociative anesthetic introduced in the 1960s, has re-emerged as a versatile therapeutic agent extending beyond its traditional perioperative role. Its rapid antidepressant action in treatment-resistant depression and efficacy in acute and chronic pain syndromes have driven what is termed the “ketamine renaissance.” Unlike conventional monoaminergic antidepressants, ketamine...
European Archives of Psychiatry and Clinical Neuroscience
June 30, 2026
C Hohoff, T Lange, L Steinbach et al.
Treatment resistance (TR) in major depressive disorder (MDD) affects a substantial minority of patients and is hard to recognize early, delaying intensified care. The Esketamine multi-omic biomarker evaluation in MDD (EMBER-MDD) is a non-interventional, investigator-initiated, in-vitro study within the EU Psych-STRATA programme, analyzing biospecimens collected in the randomized INTENSIFY study...
International Journal of Drug Delivery Technology
June 30, 2026
Angelin Grace Thomas, Dhivyaprasath Palaniappan, Sagar Guruswamy et al.
Major depressive disorder, or MDD, is a common cause of disability around the world. Treatment-resistant depression, or TRD, is a tough challenge. Many people do not respond well to treatment, which increases the risk of relapse and suicide. Esketamine is a new treatment that comes as a nasal spray. It works quickly and targets a specific brain receptor. This review looks at research from...
Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater
June 30, 2026
Cielo A Estela-Fernandez, Reem Mohamed Yousif Elsheikh, Dal Bianco Beatrice et al.
Major depressive disorder (MDD) is a heterogeneous, debilitating disorder. A distinct subgroup within the MDD spectrum is identified to have treatment-resistant depression (TRD). There is an impetus to find alternative treatments for TRD to reduce disease burden and improve quality of life. Psychedelics have been used in the treatment of various psychiatric disorders since the 1950s, with...
Pharmacology, biochemistry, and behavior
June 30, 2026
Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.
Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without...
Journal of Clinical Psychology
June 29, 2026
Ofra Walter, Sanford Nidich, Kimia Shahrokhi
The mass evacuation of Israeli residents from conflict zones after the events of October 7, 2023, coupled with ongoing security threats, has taken a substantial psychological toll, with many individuals exhibiting symptoms of post-traumatic stress disorder (PTSD), anxiety, and sleep problems. This pilot study examined the feasibility and preliminary within-group changes associated with...
Journal of Affective Disorders
June 29, 2026
Yao Ge, Lijuan Chen, Yu Shen et al.
Major depressive disorder (MDD) ranks among the foremost contributors to disability worldwide, yet its neurophysiological mechanisms remain poorly understood. Excitation-inhibition (E/I) imbalance has been implicated in MDD pathophysiology, but cortex-wide E/I ratio and its molecular substrates in MDD remain unknown. Resting-state functional magnetic resonance imaging data from 254 MDD patients...
Asian J Psychiatr
June 28, 2026
B. Vivekanand, Kanika Sethi, Eesha Sharma et al.
Rapid clinical improvement after intravenous ketamine in an adolescent with treatment-resistant depression, severe obesity, and pseudo-Cushing syndrome: A case report.
The Brown University Psychopharmacology Update
June 28, 2026
An individualized one‐day dosing regimen of a vaporized formulation of the psychedelic mebufotenin (5‐methoxy‐ N,N ‐dimethyltryptamine; 5‐MeO‐DMT) was more effective than placebo in improving depressive symptoms in adults with treatment‐resistant depression, a Phase 2b trial has found. No serious treatment‐emergent adverse events were reported during the 7‐day study. Results were published...
Geriatric nursing (New York, N.Y.)
June 27, 2026
Lily Man Lee Chan, Edmond Pui Hang Choi, Peter M. Wayne et al.
To explore the associations between mindfulness, psychological distress, and health-related quality of life (HRQOL), and examine whether psychological distress mediates the association between mindfulness and HRQOL in individuals with Parkinson's disease (PD). This is a secondary analysis of baseline data from a clinical trial investigating mindfulness-based interventions in patients with...
Academic Journal of Neuropsychiatry and Neuropsychology
June 27, 2026
Abdullah Burak Uygur, Kadir Karakuş, Selime Çelik Erden et al.
The U.S. Food and Drug Administration (FDA) has increasingly focused on breakthrough molecular mechanisms, rapidly acting medications, and expanded therapeutic indications in the treatment of depression. During this period, psychiatric interventions targeting N-methyl-D-aspartate (NMDA) receptors and intracellular signaling pathways have gained prominence, moving beyond the traditional...
Healthcare (Basel, Switzerland)
June 26, 2026
Sharmistha Roy, Amar Kanekar, Ashis Kumar Biswas et al.
Background/Objectives: University students commonly experience psychological distress driven by academic demands, social transitions, and financial pressures. Mindfulness-based interventions have emerged as scalable approaches to improve mental health. However, evidence comparing their effectiveness across delivery formats remains limited. This systematic review aimed to evaluate the...
Medicine
June 26, 2026
Ruixue Liu, Chunxiao Liu, Chunhui Li et al.
Dextromethorphan-bupropion, a novel oral N-methyl-D-aspartate receptor antagonist approved by the Food and Drug Administration in August 2022, launched in the United States in October 2022 for major depressive disorder. We aimed to detect and characterize the adverse events (AEs) of dextromethorphan-bupropion using the FDA adverse event reporting system from the 4th quarter of 2022 to the 4th...
bioRxiv (Cold Spring Harbor Laboratory)
June 26, 2026
Paulina Clara Dagnino, Irene Acero-Pousa, Robin Carhart-Harris et al.
Abstract A central challenge in neuroscience is understanding how the human brain is organised to support optimal functioning and adaptability. One approach to characterise complex brain dynamics is by artificially perturbing whole-brain models. Here, we asked whether whole-brain organisation under perturbation in major depressive disorder (MDD) changes after intervention with psilocybin and...
International Journal of Innovative Technologies in Social Science
June 25, 2026
Wojciech Kotlarski, Klaudia Magdalena Kotlarska, Tomasz Stanisław Mainka et al.
Introduction: Treatment-resistant depression (TRD) is a major public health and societal challenge, associated with persistent symptoms, functional impairment, and increased healthcare and economic burden. Intranasal esketamine has emerged as a rapid-acting adjunctive therapy with a distinct glutamatergic mechanism of action. This systematic review summarizes current evidence on its...
Clinical Neuropsychopharmacology and Addiction
June 25, 2026
Luca Persico, Giacomo D’andrea, Clara Cavallotto et al.
Background: Intranasal esketamine (ESK-NS) is an effective treatment for treatment-resistant depression (TRD), but whether antidepressant outcomes differ by sex and age remains insufficiently explored. Methods: This secondary analysis of the REAL-ESK study included 210 patients with TRD treated with ESK-NS in routine clinical practice and assessed at baseline (T0), one month (T1), and three...
Journal of psychopharmacology (Oxford, England)
June 25, 2026
Joost C Van Mechelen, Tobias A Wieles, Laura Borghans et al.
Oral S-ketamine (S-KETPO) is being explored as an alternative to intravenous maintenance treatment (S-KETIV) in treatment-resistant depression (TRD). However, the first-pass effect with S-KETPO significantly alters S-ketamine's bioavailability and the systemic exposure of its active metabolites, raising potential safety and efficacy concerns. This study characterized the pharmacodynamic and...
Molecular Psychiatry
June 25, 2026
Clotilde Guidetti, Maurizio Fava, George I. Papakostas
Major depressive disorder (MDD) and treatment-resistant depression (TRD) are prevalent and debilitating conditions. Over 50% of patients have inadequate response to first-line serotonergic antidepressants and are left with suboptimal treatment options. Rapid-acting and individually tailored treatments for MDD remain major unmet needs. This review discusses promising rapid-acting treatments,...
International Journal of Innovative Technologies in Social Science
June 24, 2026
Aleksandra Łoś, Kacper Szkodziński, Inga Jakubczyk et al.
Introduction: Depressive disorders are one of the greatest public health challenges worldwide, affecting up to 16% of the population over a lifetime and significantly impacting quality of life, disability, and premature mortality. Major depressive disorder (MDD) is a leading cause of disability, despite the availability of numerous treatment options. In 20–50% of patients, traditional...
International Journal of Innovative Technologies in Social Science
June 24, 2026
Irmina Grygutis, Oskar Mikołajczyk, Kornelia Julia Fimiarz et al.
Background: Treatment-resistant depression (TRD) is associated with substantial functional impairment, suicide risk, and health-care costs. Ketamine and its S-enantiomer, esketamine, have emerged as rapid-acting glutamatergic treatment options for TRD. Aim: This review aims to synthesize current evidence on the different ketamine administration routes for TRD, with a focus on acute and...
Journal of Psychopharmacology
June 23, 2026
Lenka Seillier, Alexandre Seillier, Morgan A. Zvolska et al.
BACKGROUND: Major depressive disorder is one of the most debilitating psychiatric disorders worldwide. First-line treatments such as selective serotonin reuptake inhibitors have significant limitations, including delayed onset of therapeutic effects and treatment resistance in about 30% of patients. Increasing evidence suggests that acute administration of serotonergic psychedelics, such as...